Tianjin Juvestar Biotech Co., Ltd.

To evaluate the efficacy and safety of RZL-012 in people with moderate to severe contour bulge or excessive fullness caused by submental fat (SMF) accumulation. Efficacy was mainly evaluated by the Clinician Submental Fat Assessment Tool (C-CAT) and the Subject Self-Assessment Tool (S-CAT). The changes in SMF fullness rated by clinicians and subjects were evaluated using the Clinician Submental Fat Assessment Tool (C-CAT) and the Subject Self-Assessment Tool (S-CAT) (week 12 compared with baseline) in the RZL-012 group and the placebo group.